Opinion|Videos|November 18, 2026

Switching Within or Across Drug Classes Safely in MG

Once a change in therapy is needed, the next question is whether to stay within the FcRn class or change mechanisms. Transition strategy matters because loss of disease control during a prolonged washout can carry meaningful clinical risk.

In this episode, ‘Switching Within or Across Drug Classes Safely in MG,’ the panel of neuromuscular experts explores how clinicians choose the next therapy when an FcRn-targeted treatment provides suboptimal control. Faculty describe circumstances in which a within-class switch may be reasonable, particularly when a patient appears to respond to FcRn inhibition but has practical issues, adverse effects, or incomplete control with a particular molecule or dosing strategy. By contrast, more severe disease or insufficient evidence that the mechanism is providing benefit may support moving to another therapeutic class.

The discussion then turns to the practical challenges of transitioning from FcRn inhibition to treatments with different mechanisms, particularly antibody-based therapies. The panel emphasizes that prolonged washout periods can leave patients vulnerable to clinical deterioration because many patients remain highly dependent on active therapy. Experts describe aligning initiation of the next agent with the timing of a patient's prior FcRn treatment rather than allowing a prolonged untreated interval.

Vaccination planning can help facilitate future use of complement inhibitors, while conventional immunosuppressants or short-term corticosteroids may provide additional coverage during transitions. Faculty also note that different agents may create different transition considerations depending on whether they are monoclonal antibodies or nonantibody therapies. The overarching principle is to maintain disease control while minimizing potentially clinically important gaps in treatment.

The next episode in this series, ‘Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence,’ features the panelists examining the slower onset and potential durability of B-cell–directed therapies and the role of FcRn inhibition as a bridge while those treatments become effective.


Related to this article